



## OUR DNA: IMPACT COMPANY

*“Our mission is to contribute to the improvement and protection of the health of populations across the world.*

*The fair sharing of the value created with all our employees is the foundation of our business model.*

*The sustainability of MedinCell is an essential condition for achieving our objectives.”*

“Raison d’être” of MedinCell voted by the General Assembly in September 2019

# CONTENT

## Corporate overview

## Framework: UN Global Compact & Sustainable Development Goals

## Social impact, at the core of our mission

- Developed counties: better care + impact on healthcare systems
- Low- and middle-income countries (LMICs): Better care + affordability

## Environmental impact

- Reducing medical waste

## ESG Governance

- 2022, Implementation of the ESG committee at board level

## ESG Ratings



# CORPORATE OVERVIEW

### ADDRESSING UNMET NEEDS WITH INNOVATIVE TREATMENTS, ALL BASED ON BREAKTHROUGH LONG-ACTING INJECTABLES TECHNOLOGY

- 8** human health products in development
- 4** products based on WHO essential medicine list
- 2** programs with Global Access Strategy

### REDUCING ENVIRONMENTAL FOOTPRINT OF TREATMENTS

- up to 90%** reduction of active compound vs oral treatment (company estimation for local delivery)

### 150 EMPLOYEES OF 30 NATIONALITIES HIGHLY INVOLVED

- 84%** of employees are shareholders  
All employees get shares after one year of employment

### ESG COMMITTEE AT BOARD LEVEL IMPLEMENTED IN 2022

# 50%


of patients do not take  
their medicines as intended

NHS England 2019

*“Increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments.”*

Haynes RB (2001) in WHO Adherence to long-term therapies: Evidence for action (2003)

# MedinCell's LAI technology platform allows to get better treatment into many indications



- ①

Financial support from the Bill & Melinda Gates Foundation for Global Access
- ②

Financed by Unitaid, Global Health
- ③

Additional indication for mdc-IRM
- ④

No further investment planned, strategy under review

\*An IND in the US (Investigational New Drug) or a CTA in Europe (Clinical Trial Application) is a request for authorization to administer an investigational drug to humans with the objective to collect clinical data (e.g., safety, PK, efficacy, ...)



## **ESG FRAMEWORK**


# **UN GLOBAL COMPACT & THE SUSTAINABLE DEVELOPMENT GOALS**

# We support Sustainable Development Goals & the UN Global Compact

MedinCell is a UN Global Compact signatory since 2021



SUSTAINABLE DEVELOPMENT GOALS



3 • We develop innovative and affordable medicine and strive to make them as accessible as possible.

5 • We strive to empower women by developing a contraceptive product that meets their needs and is widely available.

6 • BEPO®, our Long-Acting Injectable technology, addresses the issue of water contamination due to pharmaceutical residues through significantly reducing the amount of active ingredient needed in comparison to oral treatments.

17 • We promote collaboration by developing a high-value network of partners from the pharmaceutical industry, academia, NGOs, etc.






















# **SOCIAL IMPACT**

## AT THE CORE OF OUR MISSION



# We support Sustainable Development Goals & the UN Global Compact

	Challenge	Main associated SDGs
<b>Schizophrenia franchise</b> <ul style="list-style-type: none"> <li>• mdc-IRM (UZEDY™)</li> <li>• mdc-TJK</li> <li>• mdc-ANG</li> </ul>	<p>Whereas adherence is crucial in successful treatment of schizophrenia, 75% of patients had discontinued medication within 2 years.<sup>1</sup></p> <p>Annual schizophrenia costs are estimated between \$134 and \$174 bn in the U.S.<sup>2</sup></p>	  
<b>Post-operative pain management</b> <ul style="list-style-type: none"> <li>• mdc-CWM</li> </ul>	<p>Need to facilitating recovery for patients who undergo Total Knee Replacement (TKR) and accelerating improvement in knee function.</p> <p>15% of TKR patients become long-term opioid users.<sup>3</sup></p>	  
<b>Organ transplant</b> <ul style="list-style-type: none"> <li>• mdc-GRT</li> </ul>	<p>Ensuring compliance may reduce graft rejection as Non-adherence is responsible for nearly 20% of antibody-mediated rejections and 16% of early graft losses.<sup>4</sup></p>	  
<b>Covid-19 prophylaxis</b> <ul style="list-style-type: none"> <li>• mdc-TTG</li> </ul>	<p>Need additional solution to offer protection for vulnerable populations.</p>	  
<b>Contraception</b> <ul style="list-style-type: none"> <li>• mdc-WWM</li> </ul>	<p>74 million women become pregnant unintentionally every year leading to 25 million unsafe abortions and 47,000 maternal deaths.<sup>5</sup></p>	   
<b>Malaria</b> <ul style="list-style-type: none"> <li>• mdc-STM</li> </ul>	<p>Malaria in 2020: 627,000 deaths, 95% in Africa, 80% children under 5.<sup>6</sup></p>	  

<sup>1</sup> Velligan DI, et al. Psychiatr Serv. 2003;54(5):655-667. Weinstein PJ, et al. Medication noncompliance in schizophrenia: I. assessment. Journal of Practical Psychiatry and Behavioral Health. 1997;3:106-110; <sup>2</sup> Analysis Group, Otsuka, Lundbeck LLC - 2016; <sup>3</sup> 2018 Choices Matter Survey - Exposing a silent gateway to persistent opioid use; Detecting, preventing and treating non-adherence to immunosuppression after kidney transplantation Ilaria Gandolfini, Alessandra Palmisano, Enrico Fiaccadori, Paolo Cravedi<sup>3</sup> and Umberto Maggiore - Clinical Kidney Journal, 2022, vol. 15, no. 7, 1253-1274; <sup>4</sup> WHO

## SOCIAL IMPACT > Large quantities & low COGs needed for LMICs and humanitarian projects



50/50 Joint-Venture with Corbion to provide BEPO polymers for all programs

Dual GMP manufacturing facilities – Europe and U.S.

Up to 100 Kg batches (c. 2 million doses)

COGs compatible with large scale humanitarian requirement & LMICs needs



Leading manufacturer of biomedical polymers worldwide

Pharma production standards (ICHQ & GMP)

Listed on Euronext Amsterdam (CRBN - market cap: c. €2.1 B as of March 1<sup>st</sup>, 2023)



# ENVIRONMENTAL IMPACT

## REDUCING MEDICAL WASTE

**up to  
90%** reduction of active compound  
vs oral treatment  
*(MedinCell's estimation for local delivery)*

The BEPO® technology makes it possible to design products with a reduced impact on the environment through two factors:


- Reducing the amount of active ingredient needed to treat a patient through improved bioavailability of the active ingredient and/or targeted action
- Elimination of the inappropriate and polluting disposal of active ingredients not uptaken by patients



## GOVERNANCE


A SUSTAINABLE COMPANY TO PRESERVE THE MISSION

## ESG GOVERNANCE > 2022, Implementation of the ESG committee at board level



### Mission

- Ensure that all activities of the company are aligned with its core mission / raison d'être
- Encourage comprehensive ESG initiatives at MedinCell & continuous improvement
- Review the ESG company objectives and strategy
- Evaluate ESG policy and results
- Endorse ESG report



ESG commitments, initiatives and actions

Available on [www.medincell.com](http://www.medincell.com)



# ESG RATINGS



## ESG Performance: Prime Status obtained from ISS ESG



**ESG Performance Rating**  
**B- / Prime status**  
**Top 10% of the Pharma / Biotech sector**  
*(January 2023)*



**Rating: C**  
(December 2022)  
Sector average rating: B-



**ESG Risk Rating: Medium (29.7)**  
(November 2022)  
Subindustry ranking: 69/430



**Score: 76**  
(October 2022)  
French companies average score: 45



contact: [communication@medincell.com](mailto:communication@medincell.com)